TOKYO, Mar 25 (Pulse News Wire) – Takeda Pharmaceutical Company Limited (4502.T) announced today that its board approved further steps aimed at enhancing competitiveness and accelerating growth through cost-cutting measures. The changes, expected to reduce costs by more than ¥200.0 billion annually by fiscal 2028, will streamline corporate functions and bring leadership closer to patients and customers while simplifying processes with advanced technology.
As part of these efforts, Takeda anticipates incurring approximately ¥150.0 billion in restructuring expenses during fiscal 2026. These costs will be reflected in the company's forecast for the fiscal year ending March 2026, which will be disclosed along with the full-year results scheduled for release later this year. Restructuring expenses for fiscal 2027 and 2028 are projected to be lower.
The company believes these initiatives will strengthen its foundation for long-term growth and future success. Incoming CEO Julie Kim stated, “We are building the groundwork to enrich patients' lives through multiple new product launches and maximizing pipeline value. Our strategic optimization and enhanced execution capabilities aim to solidify our base for sustained growth.”.
🟡 Confidence: Standard AI-translated content.